Efficacy and Safety of 4 Fractions of Carbon-Ion Radiation Therapy for Hepatocellular Carcinoma: A Prospective Study
Introduction: Prospective evidence supporting the safety and efficacy of carbon-ion radiotherapy (C-ion RT) for hepatocellular carcinoma (HCC) remains lacking. This prospective study aimed to evaluate the safety and efficacy of hypofractionated C-ion RT in patients with HCC. Methods: The inclusion c...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2021-12-01
|
| Series: | Liver Cancer |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/520277 |
| _version_ | 1798019734883532800 |
|---|---|
| author | Kei Shibuya Hiroyuki Katoh Yoshinori Koyama Shintaro Shiba Masahiko Okamoto Shohei Okazaki Kenichiro Araki Satoru Kakizaki Ken Shirabe Tatsuya Ohno |
| author_facet | Kei Shibuya Hiroyuki Katoh Yoshinori Koyama Shintaro Shiba Masahiko Okamoto Shohei Okazaki Kenichiro Araki Satoru Kakizaki Ken Shirabe Tatsuya Ohno |
| author_sort | Kei Shibuya |
| collection | DOAJ |
| description | Introduction: Prospective evidence supporting the safety and efficacy of carbon-ion radiotherapy (C-ion RT) for hepatocellular carcinoma (HCC) remains lacking. This prospective study aimed to evaluate the safety and efficacy of hypofractionated C-ion RT in patients with HCC. Methods: The inclusion criteria were as follows: (1) pathologically or clinically diagnosed HCC; (2) measurable tumor and tumor size ≤10 cm; (3) absence of major vascular invasion; (4) no extrahepatic metastasis; (5) the alimentary tract was not adjacent to the target lesion (>1 cm); (6) not suitable for or refusal to undergo surgery or local ablative therapies; (7) an interval ≥4 weeks from previous therapy; (8) no other intrahepatic lesion or at least 2 years after the previous curative therapy; (9) performance status score, 0–2; and (10) Child-Pugh score, 5–9. The prescribed C-ion RT dose was 52.8 Gy (relative biological effectiveness [RBE]) or 60.0 Gy (RBE) in 4 fractions. Results: In total, 35 patients with HCC were enrolled between October 2010 and May 2016. The median follow-up durations in the survivor group (n = 23) and in the whole cohort were 55.1 and 49.0 months, respectively. The 2-, 3-, and 4-year overall survival rates were 82.8%, 76.7%, and 69.4%, respectively. The 2-, 3-, and 4-year local control (LC) rates were 92.6%, 76.5%, and 76.5%, respectively. The median time-to-progression was 25.6 months (95% confidence interval, 13.7–37.5 months). Grade 4 or 5 toxicities were not observed. Grade 3 acute and late toxicities were observed in 2 patients. There was no significant deterioration in serum albumin, bilirubin, prothrombin time-international normalized ratio, platelet count, or Child-Pugh score after C-ion RT. Conclusion: Four fractions of C-ion RT for HCC did not yield serious adverse events and showed promising LC, thus making it a safe and effective modality for this type of malignancy. |
| first_indexed | 2024-04-11T16:45:43Z |
| format | Article |
| id | doaj.art-06d352a4ade044379688ed0ff5300158 |
| institution | Directory Open Access Journal |
| issn | 2235-1795 1664-5553 |
| language | English |
| last_indexed | 2024-04-11T16:45:43Z |
| publishDate | 2021-12-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Liver Cancer |
| spelling | doaj.art-06d352a4ade044379688ed0ff53001582022-12-22T04:13:34ZengKarger PublishersLiver Cancer2235-17951664-55532021-12-01111617410.1159/000520277520277Efficacy and Safety of 4 Fractions of Carbon-Ion Radiation Therapy for Hepatocellular Carcinoma: A Prospective StudyKei Shibuya0Hiroyuki Katoh1Yoshinori Koyama2Shintaro Shiba3Masahiko Okamoto4Shohei Okazaki5Kenichiro Araki6Satoru Kakizaki7https://orcid.org/0000-0003-0224-7093Ken Shirabe8Tatsuya Ohno9Gunma University Heavy Ion Medical Center, Maebashi, JapanDepartment of Radiation Oncology, Kanagawa Cancer Center, Yokohama, JapanDepartment of Diagnostic Radiology, Shibukawa Medical Center, Shibukawa, JapanGunma University Heavy Ion Medical Center, Maebashi, JapanGunma University Heavy Ion Medical Center, Maebashi, JapanGunma University Heavy Ion Medical Center, Maebashi, JapanDivision of Hepatobiliary and Pancreatic Surgery, Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, JapanDepartment of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi, JapanDivision of Hepatobiliary and Pancreatic Surgery, Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, JapanGunma University Heavy Ion Medical Center, Maebashi, JapanIntroduction: Prospective evidence supporting the safety and efficacy of carbon-ion radiotherapy (C-ion RT) for hepatocellular carcinoma (HCC) remains lacking. This prospective study aimed to evaluate the safety and efficacy of hypofractionated C-ion RT in patients with HCC. Methods: The inclusion criteria were as follows: (1) pathologically or clinically diagnosed HCC; (2) measurable tumor and tumor size ≤10 cm; (3) absence of major vascular invasion; (4) no extrahepatic metastasis; (5) the alimentary tract was not adjacent to the target lesion (>1 cm); (6) not suitable for or refusal to undergo surgery or local ablative therapies; (7) an interval ≥4 weeks from previous therapy; (8) no other intrahepatic lesion or at least 2 years after the previous curative therapy; (9) performance status score, 0–2; and (10) Child-Pugh score, 5–9. The prescribed C-ion RT dose was 52.8 Gy (relative biological effectiveness [RBE]) or 60.0 Gy (RBE) in 4 fractions. Results: In total, 35 patients with HCC were enrolled between October 2010 and May 2016. The median follow-up durations in the survivor group (n = 23) and in the whole cohort were 55.1 and 49.0 months, respectively. The 2-, 3-, and 4-year overall survival rates were 82.8%, 76.7%, and 69.4%, respectively. The 2-, 3-, and 4-year local control (LC) rates were 92.6%, 76.5%, and 76.5%, respectively. The median time-to-progression was 25.6 months (95% confidence interval, 13.7–37.5 months). Grade 4 or 5 toxicities were not observed. Grade 3 acute and late toxicities were observed in 2 patients. There was no significant deterioration in serum albumin, bilirubin, prothrombin time-international normalized ratio, platelet count, or Child-Pugh score after C-ion RT. Conclusion: Four fractions of C-ion RT for HCC did not yield serious adverse events and showed promising LC, thus making it a safe and effective modality for this type of malignancy.https://www.karger.com/Article/FullText/520277hepatocellular carcinomaheavy ion radiotherapycarbon-ion radiotherapyprospective |
| spellingShingle | Kei Shibuya Hiroyuki Katoh Yoshinori Koyama Shintaro Shiba Masahiko Okamoto Shohei Okazaki Kenichiro Araki Satoru Kakizaki Ken Shirabe Tatsuya Ohno Efficacy and Safety of 4 Fractions of Carbon-Ion Radiation Therapy for Hepatocellular Carcinoma: A Prospective Study Liver Cancer hepatocellular carcinoma heavy ion radiotherapy carbon-ion radiotherapy prospective |
| title | Efficacy and Safety of 4 Fractions of Carbon-Ion Radiation Therapy for Hepatocellular Carcinoma: A Prospective Study |
| title_full | Efficacy and Safety of 4 Fractions of Carbon-Ion Radiation Therapy for Hepatocellular Carcinoma: A Prospective Study |
| title_fullStr | Efficacy and Safety of 4 Fractions of Carbon-Ion Radiation Therapy for Hepatocellular Carcinoma: A Prospective Study |
| title_full_unstemmed | Efficacy and Safety of 4 Fractions of Carbon-Ion Radiation Therapy for Hepatocellular Carcinoma: A Prospective Study |
| title_short | Efficacy and Safety of 4 Fractions of Carbon-Ion Radiation Therapy for Hepatocellular Carcinoma: A Prospective Study |
| title_sort | efficacy and safety of 4 fractions of carbon ion radiation therapy for hepatocellular carcinoma a prospective study |
| topic | hepatocellular carcinoma heavy ion radiotherapy carbon-ion radiotherapy prospective |
| url | https://www.karger.com/Article/FullText/520277 |
| work_keys_str_mv | AT keishibuya efficacyandsafetyof4fractionsofcarbonionradiationtherapyforhepatocellularcarcinomaaprospectivestudy AT hiroyukikatoh efficacyandsafetyof4fractionsofcarbonionradiationtherapyforhepatocellularcarcinomaaprospectivestudy AT yoshinorikoyama efficacyandsafetyof4fractionsofcarbonionradiationtherapyforhepatocellularcarcinomaaprospectivestudy AT shintaroshiba efficacyandsafetyof4fractionsofcarbonionradiationtherapyforhepatocellularcarcinomaaprospectivestudy AT masahikookamoto efficacyandsafetyof4fractionsofcarbonionradiationtherapyforhepatocellularcarcinomaaprospectivestudy AT shoheiokazaki efficacyandsafetyof4fractionsofcarbonionradiationtherapyforhepatocellularcarcinomaaprospectivestudy AT kenichiroaraki efficacyandsafetyof4fractionsofcarbonionradiationtherapyforhepatocellularcarcinomaaprospectivestudy AT satorukakizaki efficacyandsafetyof4fractionsofcarbonionradiationtherapyforhepatocellularcarcinomaaprospectivestudy AT kenshirabe efficacyandsafetyof4fractionsofcarbonionradiationtherapyforhepatocellularcarcinomaaprospectivestudy AT tatsuyaohno efficacyandsafetyof4fractionsofcarbonionradiationtherapyforhepatocellularcarcinomaaprospectivestudy |